CLPT Stock Forecast: ClearPoint Neuro, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for ClearPoint Neuro, Inc. is $22. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores ClearPoint Neuro, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (86): Analysts have, on balance, been raising their forecasts.
Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CLPT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CLPT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Oct 2026 | Stifel | Maintains | Buy | $22 → $18 |
| 18 June 2026 | B. Riley Securities | Maintains | Buy | $20 → $30 |
| 18 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 5 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 1 Aug 2025 | Stifel | Maintains | Buy | — |
| 25 Apr 2025 | B. Riley Securities | Maintains | Buy | — |
| 1 Apr 2025 | Stifel | Maintains | Buy | — |
| 28 Jan 2025 | B. Riley Securities | Maintains | Buy | — |
| 21 Jan 2025 | Lake Street | Maintains | Buy | — |
| 27 Aug 2024 | Lake Street | Maintains | Buy | — |
| 13 Mar 2024 | Stifel | Reiterates | Buy | — |
| 24 Oct 2023 | Stifel | Initiates | Buy | — |
| 9 Aug 2023 | Lake Street | Maintains | Buy | — |
| 16 Feb 2023 | B. Riley Securities | Reinstates | Buy | $14 |
| 5 Apr 2022 | B. Riley Securities | Reinstates | Buy | $15 |
| 18 Mar 2021 | Lake Street | Initiates | Buy | — |
| 17 July 2020 | B. Riley Securities | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CLPT.
This page is one stock. Monday covers all of them.
CLPT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CLPT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, ClearPoint Neuro, Inc. returned −48.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CLPT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 5.2×
- Price / book
- 8.6×
- EV / EBITDA
- —
Cheaper than 21% of US stocks
Cheaper than 9% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 61.7%
- Operating margin
- −66.6%
- Net margin
- −79.4%
Higher than 75% of US stocks
Higher than 17% of US stocks
Higher than 7% of US stocks
- Return on equity
- −167.5%
- Return on assets
- −21.9%
- Dividend yield
- —
Higher than 9% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ClearPoint Neuro, Inc. has a market value of $234.3M and an enterprise value of $261.8M.
Revenue in the twelve months to 30 June 2026: $42.3M. The latest quarter grew 18.1% year on year.
Net income over the same four quarters: −$34.6M, a −81.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$31.3M.
ClearPoint Neuro, Inc. employs 172 people — $246K of revenue per employee.
Data provided by Twelve Data
CLPT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CLPT’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own ClearPoint Neuro, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CLPT
What is the CLPT stock price forecast for 2026-2027?
The median 12-month analyst price target for ClearPoint Neuro, Inc. is $22, with estimates ranging from $18 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CLPT stock a buy right now?
Of the 2 analysts covering ClearPoint Neuro, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ClearPoint Neuro, Inc. 29 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CLPT?
As at 21 Nov 2026, ClearPoint Neuro, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (86 of 100).
Will CLPT stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $22, and Ticker Nerd's factor model ranks ClearPoint Neuro, Inc. 29 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CLPT stock forecast for 2030?
No analyst covering ClearPoint Neuro, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $25 over the next 12 months.
How has CLPT stock performed over the past year?
ClearPoint Neuro, Inc. returned -48.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does ClearPoint Neuro, Inc. do?
ClearPoint Neuro Inc. is a medical technology company focused on precision navigation and delivery solutions for complex neurological procedures. The company develops and commercializes platforms used in minimally invasive brain and spine interventions, combining hardware, disposable instruments, and software that support surgical planning, targeting, and procedure monitoring.
About ClearPoint Neuro, Inc.
ClearPoint Neuro Inc. is a medical technology company focused on precision navigation and delivery solutions for complex neurological procedures. The company develops and commercializes platforms used in minimally invasive brain and spine interventions, combining hardware, disposable instruments, and software that support surgical planning, targeting, and procedure monitoring. Its product portfolio includes MRI-guided navigation systems, laser therapy tools, and therapy-delivery components designed to help clinicians access hard-to-reach areas of the central nervous system with greater control. ClearPoint Neuro also provides enabling services for cell, gene, and drug delivery programs, supporting medical and research partners with preclinical and clinical development workflows. The company serves healthcare and research centers across multiple global regions, making it an important specialist in image-guided neurosurgical technology and therapeutic delivery.
CEO Mr. Joseph Michael Burnett · 172 employees · United States · https://www.clearpointneuro.com